# A Study of Multiple Doses of Nusinersen (ISIS 396443) Delivered to Infants With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy

> **NCT02386553** · PHASE2 · COMPLETED · sponsor: **Biogen** · enrollment: 25 (actual)

## Conditions studied

- Spinal Muscular Atrophy

## Interventions

- **DRUG:** Nusinersen

## Key facts

- **NCT ID:** NCT02386553
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-05-18
- **Primary completion:** 2024-12-17
- **Final completion:** 2024-12-17
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2025-10-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02386553

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02386553, "A Study of Multiple Doses of Nusinersen (ISIS 396443) Delivered to Infants With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT02386553. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*